In this study, we comprehensively evaluated the role of NAT10 and the therapeutic effects of the NAT10 inhibitor Remodelin in CRC by integrating transcriptomic, genetic, and epigenetic analysis using clinical samples, cell lines, and xenograft mouse models. Here, NAT10 is linked to colorectal carcinoma.